Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

June 4, 2024

https://www.globenewswire.com/news-release/2024/06/04/2893440/0/en/Abivax-releases-the-results-of-its-May-30-2024-Ordinary-and-Extraordinary-General-Meeting.html

PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq:ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.